The chance appearance of certain combinations of elements in the genome can lead to the generation of new genes that drive evolutionary innovation.
The chance appearance of certain combinations of elements in the genome can lead to the generation of new genes that drive evolutionary innovation.
In experimental models of lung cancer, researchers have found that a combination of two drugs plus radiation can help treat resistant lung cancers which are susceptible to therapy.
[adsense:336x280:8701650588]
The humble saffron has come to rescue people who are at the risk of developing liver cancer. A biomolecule found in the golden spice is good for your liver, find the researchers.
A gene-editing technique has shown promise in treating Duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy among boys which is characterised by progressive muscle degeneration and weakness.
Researchers have developed new polio vaccine strains that is particularly suitable for a post-eradication era as these strains appear both effective and unable to cause disease after accidental release.
Pharma major Cadila Healthcare on Thursday clarified that products from its Moraiya and Ahmedabad plants in Gujarat were safe in the market and effective.
Taking a high dose of vitamin D could be an inexpensive and easy way to treat people with multiple sclerosis (MS), an autoimmune disorder that affects the brain and spinal chord, suggests promising new research.
The city-based Asian Institute of Gastroenterology on Wednesday claimed that it successfully used a new technique for treatment of gastro-esophageal reflux disease (GERD), usually termed as acidity.
Formulating drugs as liquid salts may provide a safe and efficient strategy for topical delivery of drugs that cause skin toxicity, say researchers, including one of Indian-origin. A novel formulation of the drug propranolol as a liquid salt enables delivery through skin with reduced toxicity, the findings showed.
[adsense:336x280:8701650588]
Daiichi Sankyo Company, Limited announced that its wholly owned subsidiary, Daiichi Sankyo Korea Co., Ltd. (hereafter “DSKR;” headquarters: Jongno-gu, Seoul, South Korea), and Daewoong Pharmaceutical Co., Ltd. (hereafter “Daewoong Pharmaceutical;” headquarter: Gangnam-gu, Seoul, South Korea) have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA® (generic name: edoxaban).